Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Evolus Inc (EOLS)

Evolus Inc (EOLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 538,512
  • Shares Outstanding, K 56,095
  • Annual Sales, $ 99,670 K
  • Annual Income, $ -46,810 K
  • 60-Month Beta 1.95
  • Price/Sales 5.26
  • Price/Cash Flow N/A
  • Price/Book 11.49
Trade EOLS with:

Options Overview Details

View History
  • Implied Volatility 90.32% ( -7.07%)
  • Historical Volatility 84.77%
  • IV Percentile 70%
  • IV Rank 41.42%
  • IV High 125.80% on 05/06/22
  • IV Low 65.23% on 08/18/21
  • Put/Call Vol Ratio 0.09
  • Today's Volume 82
  • Volume Avg (30-Day) 209
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 7,038
  • Open Int (30-Day) 5,780

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.35
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.91 +7.74%
on 08/09/22
14.29 -32.82%
on 07/20/22
-3.38 (-26.04%)
since 07/12/22
3-Month
8.91 +7.74%
on 08/09/22
14.34 -33.05%
on 05/17/22
-2.44 (-20.27%)
since 05/12/22
52-Week
5.06 +89.69%
on 01/24/22
14.34 -33.05%
on 05/17/22
-1.17 (-10.86%)
since 08/12/21

Most Recent Stories

More News
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EOLS : 9.60 (+2.78%)
CGC : 3.30 (+4.76%)
Evolus Reports Second Quarter 2022 Results and Provides Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the second quarter ended June...

EOLS : 9.60 (+2.78%)
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

DCPH : 16.41 (+4.06%)
EOLS : 9.60 (+2.78%)
Evolus to Report Second Quarter 2022 Results and Provide Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its second quarter 2022 financial...

EOLS : 9.60 (+2.78%)
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today launched its “Switch Your Tox and Love Evolus Forever”...

EOLS : 9.60 (+2.78%)
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has completed patient enrollment in its clinical study evaluating...

EOLS : 9.60 (+2.78%)
Does Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?

The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

EOLS : 9.60 (+2.78%)
Is Computer Programs and Systems (CPSI) Stock Outpacing Its Medical Peers This Year?

Here is how Computer Programs and Systems (CPSI) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

CPSI : 31.28 (+2.62%)
EOLS : 9.60 (+2.78%)
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that Dermatologic Surgery published a new post...

EOLS : 9.60 (+2.78%)
Wall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Evolus, Inc. (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive...

EOLS : 9.60 (+2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

3rd Resistance Point 10.27
2nd Resistance Point 10.01
1st Resistance Point 9.81
Last Price 9.60
1st Support Level 9.35
2nd Support Level 9.09
3rd Support Level 8.89

See More

52-Week High 14.34
Fibonacci 61.8% 10.80
Fibonacci 50% 9.70
Last Price 9.60
Fibonacci 38.2% 8.61
52-Week Low 5.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar